daratumumab   

GtoPdb Ligand ID: 7395

Synonyms: 3003-005 | Darzalex® | HuMax-CD38 | JNJ-54767414
daratumumab is an approved drug (FDA (2015), EMA (2017))
Compound class: Antibody
Comment: Daratumumab is a monoclonal antibody directed against CD38.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
References
1. De Weers M, Graus Y, Oprins J, Parren P, Van De Winkel J, Van Vugt M. (2010)
Antibodies Against Cd38 For Treatment Of Multiple Myeloma.
Patent number: US7829673. Assignee: Genmab A/S. Priority date: 23/03/2005. Publication date: 09/11/2010.
2. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW et al.. (2011)
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
J. Immunol., 186 (3): 1840-8. [PMID:21187443]
3. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. (2011)
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.
Blood Cancer J, 1 (10): e41. [PMID:22829073]
4. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. (2011)
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
Haematologica, 96 (2): 284-90. [PMID:21109694]
5. (2016)
A Three-Drug Combo for Multiple Myeloma.
Cancer Discov, 6 (11): OF4. [PMID:27630127]